Drug Detail

Information about None, Adriamycin

Generic Name	Flavopiridol + Doxorubicin
IND
Brand Name (US)	None, Adriamycin
Manufacturer	Aventis,
Drug Type
Delivery	Intravenous
Approval Status	Doxorubicin is approved for non-GIST cancer(s). Favopiridol is in phase 2 trials. The combination was evaluated in a phase 2 trial for sarcoma.
Indications
Overall Strategy	GIST cell based
Strategy	Freeze the cell division cycle
Drug Category	Transcription inhibitor + Chemotherapy

Doxorubicin is a traditional cytotoxic chemotherapy. The drug is administered intravenously. It may be sold under the brand names Adriamycin PFS, Adriamycin RDF, or Rubex.[2] Doxil is a liposome-encapsulated form of doxorubicin made by Ben Venue Laboratories for Johnson & Johnson.

Flavopiridol is an inhibitor of the cell cycle and an inhibitor of transcription.
Flavopiridol has been shown to inhibit the production of the KIT protein.